Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, although Sanofi-Aventis's Taxotere will remain the market leader through 2010, generic erosion of Taxotere will reduce the overall value of the taxane market between 2010 and 2015.

The new Pharmacor report Taxanes finds that the increasing use of Taxotere in chemotherapy treatment for prostate cancer and non-small-cell lung cancer and the launch of two novel taxanes, Sanofi-Aventis's larotaxel and Bayer Schering's tocosol paclitaxel, will drive growth in the market through 2010. Taxanes will continue to be the mainstay class of drugs in chemotherapy treatment through 2015; however, market decline in the second half of the study period (in the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom) will be the result of generic erosion of Taxotere and increased competition from novel targeted agents, including VEGF inhibitors and EGFR inhibitors.

The report, which covers the taxane market for breast cancer, non-small- cell lung cancer, prostate cancer, squamous cell carcinoma of the head and neck, stomach cancer, and ovarian cancer, also finds that, although there is significant unmet need associated with currently available taxanes, physicians believe novel taxanes are unlikely to address these needs.

"Taxanes have reached an efficacy plateau, allowing only modest commercial rewards for novel taxanes," said Decision Resources Analyst Marcus Hoyle. "Experts we interviewed doubt that novel taxanes will bring enough significant benefit over existing agents to warrant their premium price."

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563

Despite FDA Black Box Warning and Restriction to Second-Line Use, Clinicians Widely Use Long-Acting Beta2 Agonists as First-Line Treatment for Mild Asthma

View Now